JAB 23425
Alternative Names: JAB-23425Latest Information Update: 30 Jun 2023
At a glance
- Originator Jacobio Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action KRAS protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 01 Jun 2023 Adverse events data from a preclinical trial in Cancer released by Jacobio Pharmaceuticals
- 14 Apr 2023 Preclinical trials in Cancer in China (PO) prior to April 2023
- 14 Apr 2023 Pharmacodynamics data from a preclinical trial in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)